Coulidiaty Abdul Gafar Victoir, Youl Estelle Noëla Hoho, Yaméogo Téné Marceline, Oladoja Farouk Adedeji, Odejobi Tolulope Anuoluwapo, Ouedraogo Raogo, Awodele Olufunsho
Drug Development Laboratory (LADME), Doctoral School of Health and Sciences (ED2S), Joseph KI-ZERBO University, Ouagadougou, Burkina Faso.
Department of Hospital Pharmacy, Yalgado Ouédraogo University Hospital, Ouagadougou, Burkina Faso.
J Exp Pharmacol. 2025 May 17;17:223-237. doi: 10.2147/JEP.S523697. eCollection 2025.
Diabetes mellitus, characterized by chronic hyperglycaemia, remains a major global health burden. Limitations of conventional therapies have led to growing interest in medicinal plants like (A. Rich.) Hochst. widely used in African ethnomedicine. Though prior research has focused more on the stem bark, studies on the leaves, considered more sustainable and traditionally relevant, are still lacking in vivo data. This study assessed the antidiabetic potential of a hydroethanolic leaf extract of in Wistar rats.
The extract was tested at 25-200 mg/kg in an oral glucose tolerance test (OGTT), and at 100-400 mg/kg in normoglycemic and high fructose-fed, streptozotocin (STZ)-induced type 2 diabetic rats over 21 and 28 days, respectively. Fasting blood glucose, insulin, glycated haemoglobin (HbA1c), glucose transporter type 4 (GLUT4), haematological and biochemical parameters, and histopathological changes in key organs were evaluated.
In the OGTT, the extract significantly reduced postprandial blood glucose at 100 and 200 mg/kg starting from 60 minutes post-glucose load (p < 0.05). In normoglycemic rats, repeated administration over 21 days led to a dose-dependent and statistically significant reduction in fasting blood glucose beginning on day 14 and sustained through day 21 (p < 0.01). In diabetic rats, fasting blood glucose levels were significantly reduced from day 7 onward, with 400 mg/kg producing effects comparable to glibenclamide by day 28 (p < 0.01). Insulin, GLUT4, and HbA1c levels were not significantly altered (p > 0.05). Haematological and biochemical parameters remained within normal ranges, and histopathological examination showed preservation of pancreatic and renal tissues in treated groups.
leaf extract significantly lowers blood glucose in both normoglycemic and diabetic rats without adverse effects, supporting its potential as a safe plant-based option for diabetes management. Further research is warranted to clarify its mechanisms and long-term impact.
糖尿病以慢性高血糖为特征,仍然是全球主要的健康负担。传统疗法的局限性使得人们对像(A. Rich.)Hochst.这样在非洲民族医学中广泛使用的药用植物越来越感兴趣。尽管先前的研究更多地集中在茎皮上,但对叶子的研究,认为叶子更具可持续性且与传统医学相关,仍然缺乏体内数据。本研究评估了(A. Rich.)Hochst.叶的水乙醇提取物对Wistar大鼠的抗糖尿病潜力。
在口服葡萄糖耐量试验(OGTT)中,提取物以25 - 200 mg/kg的剂量进行测试,在正常血糖和高果糖喂养、链脲佐菌素(STZ)诱导的2型糖尿病大鼠中,分别以100 - 400 mg/kg的剂量给药21天和28天。评估空腹血糖、胰岛素、糖化血红蛋白(HbA1c)、4型葡萄糖转运蛋白(GLUT4)、血液学和生化参数以及关键器官的组织病理学变化。
在OGTT中,提取物在葡萄糖负荷后60分钟开始时,100和200 mg/kg剂量可显著降低餐后血糖(p < 0.05)。在正常血糖大鼠中,连续21天重复给药导致从第14天开始空腹血糖呈剂量依赖性且具有统计学意义的降低,并持续到第21天(p < 0.01)。在糖尿病大鼠中,空腹血糖水平从第7天开始显著降低,到第28天,400 mg/kg的效果与格列本脲相当(p < 0.01)。胰岛素、GLUT4和HbA1c水平没有显著改变(p > 0.05)。血液学和生化参数保持在正常范围内,组织病理学检查显示治疗组的胰腺和肾脏组织得以保存。
(A. Rich.)Hochst.叶提取物可显著降低正常血糖和糖尿病大鼠的血糖,且无不良反应,支持其作为糖尿病管理中一种安全的植物性选择的潜力。有必要进一步研究以阐明其机制和长期影响。